Our Team
At SL BIO, our executive management brings together cross-disciplinary experience in biotechnology, immune cell research, and early-stage therapeutic development. With collective expertise spanning T cell platform development, translational immunology, and strategic biotech operations, we are dedicated to advancing scientific discovery through rigorously designed, research-driven programs.
Our focus includes the development of investigational platforms such as Armed-T and gamma delta T cell–based approaches, which are currently in preclinical exploration. Through close collaboration with academic and industry partners, our team ensures that SL BIO operates at the forefront of innovation while maintaining high standards of scientific integrity and responsible development.
By building strong alliances and fostering a culture of scientific curiosity and precision, we are committed to supporting the advancement of immune-based platforms and expanding their future potential in translational research.
Chairman / Chief Executive Officer (CEO)
William Wang Ching-Dong
Expertise:
Business Management
Investment Management
Market Development
Cell Medicine
Chief Technology Officer (CTO)
Ethan Shen, Ph.D.
Expertise:
Translational Medicine
New Drug Development
Medical-grade health Product Development
Financial Management
Chief Financial Officer (CFO)
Ray Leung
Expertise:
Financial Accounting
Financial Management
Internal Control